Literature DB >> 30074116

Five Year Outcomes of Tapering Antipsychotic Drug Doses in a Community Mental Health Center.

Sandra Steingard1.   

Abstract

There is evidence that many individuals are on higher doses of antipsychotic drug than is required for optimal functioning yet there are limited guidelines on how to reduce them. This paper reports on 5 year outcomes for sixty-seven individuals who received treatment at a community mental health center and were offered the opportunity to gradually reduce their doses of antipsychotic drug in collaboration with the treating psychiatrist. Over a period of 6 months, the author invited patients who were clinically stable and able to participate in discussions of potential risks and benefits to begin gradual dose reductions. Initially, 40 expressed interest in tapering and 27 declined. The groups did not differ in age, sex, race, or diagnosis. The group who chose to taper began on significantly lower doses. Most patients succeeded at making modest dose reductions. At 5 years, there were no significant differences in the two outcomes measures, rate of hospitalization and employment status. Many patients were able to engage in these discussions which did not result in widespread discontinuation of drug. This is a naturalistic, small study of a topic that warrants further research.

Entities:  

Keywords:  Antipsychotics; Discontinuation; Psychosis; Schizophrenia; Tapering

Mesh:

Substances:

Year:  2018        PMID: 30074116     DOI: 10.1007/s10597-018-0313-1

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  13 in total

1.  Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study.

Authors:  Delbert G Robinson; Nina R Schooler; Majnu John; Christoph U Correll; Patricia Marcy; Jean Addington; Mary F Brunette; Sue E Estroff; Kim T Mueser; David Penn; James Robinson; Robert A Rosenheck; Joanne Severe; Amy Goldstein; Susan Azrin; Robert Heinssen; John M Kane
Journal:  Am J Psychiatry       Date:  2014-12-04       Impact factor: 18.112

2.  Clinical practice guidelines. Treatment of schizophrenia.

Authors: 
Journal:  Can J Psychiatry       Date:  2005-11       Impact factor: 4.356

Review 3.  The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia.

Authors:  Donald C Goff; Peter Falkai; W Wolfgang Fleischhacker; Ragy R Girgis; Rene M Kahn; Hiroyuki Uchida; Jingping Zhao; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2017-05-05       Impact factor: 18.112

4.  Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial.

Authors:  Lex Wunderink; Roeline M Nieboer; Durk Wiersma; Sjoerd Sytema; Fokko J Nienhuis
Journal:  JAMA Psychiatry       Date:  2013-09       Impact factor: 21.596

5.  A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia.

Authors:  Martin Harrow; Thomas H Jobe; Robert N Faull; Jie Yang
Journal:  Psychiatry Res       Date:  2017-06-22       Impact factor: 3.222

Review 6.  Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.

Authors:  Guy Chouinard; Anne-Noël Samaha; Virginie-Anne Chouinard; Charles-Siegfried Peretti; Nobuhisa Kanahara; Masayuki Takase; Masaomi Iyo
Journal:  Psychother Psychosom       Date:  2017-06-24       Impact factor: 17.659

Review 7.  Metabolic syndrome with the atypical antipsychotics.

Authors:  Pornpoj Pramyothin; Lalita Khaodhiar
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-10       Impact factor: 3.243

8.  The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia.

Authors:  C M Harding; G W Brooks; T Ashikaga; J S Strauss; A Breier
Journal:  Am J Psychiatry       Date:  1987-06       Impact factor: 18.112

Review 9.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

10.  Premature Mortality Among Adults With Schizophrenia in the United States.

Authors:  Mark Olfson; Tobias Gerhard; Cecilia Huang; Stephen Crystal; T Scott Stroup
Journal:  JAMA Psychiatry       Date:  2015-12       Impact factor: 21.596

View more
  2 in total

1.  A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.

Authors:  Mark Abie Horowitz; Sameer Jauhar; Sridhar Natesan; Robin M Murray; David Taylor
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 7.348

2.  The experiences of 585 people when they tried to withdraw from antipsychotic drugs.

Authors:  John Read
Journal:  Addict Behav Rep       Date:  2022-03-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.